Chad J. Swanson
About
Chad J. Swanson is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience.
According to data from OpenAlex, Chad J. Swanson has authored 58 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 23 papers in Molecular Biology and 17 papers in Cellular and Molecular Neuroscience. Recurrent topics in Chad J. Swanson's work include Alzheimer's disease research and treatments (26 papers), Neuroscience and Neuropharmacology Research (13 papers) and Computational Drug Discovery Methods (11 papers). Chad J. Swanson is often cited by papers focused on Alzheimer's disease research and treatments (26 papers), Neuroscience and Neuropharmacology Research (13 papers) and Computational Drug Discovery Methods (11 papers). Chad J. Swanson collaborates with scholars based in United States, United Kingdom and Japan. Chad J. Swanson's co-authors include Shobha Dhadda, Peter W. Kalivas, Lynn D. Kramer, Larisa Reyderman, Michael C. Irizarry, Ann E. Kelley, Michio Kanekiyo, Randall J. Bateman, Paul Aisen and Marwan Sabbagh and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Neuroscience.
In The Last Decade
Chad J. Swanson
56 papers receiving 6.9k citations
Hit Papers
Peers
Chad J. Swanson
Christoph Höck Switzerland
Nenad Bogdanović Sweden
Judes Poirier Canada
Zaven S. Khachaturian United States
Miloš D. Ikonomović United States
Chris G. Parsons Germany
Jeffy P. Jimenez United States
Erik D. Roberson United States
Milene L. Brownlow United States
James J. Lah United States
Citations per year, relative to Chad J. Swanson Chad J. Swanson (= 1×)
peers
Christoph Höck
Countries citing papers authored by Chad J. Swanson
Since
Specialization
Citations
This map shows the geographic impact of Chad J. Swanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chad J. Swanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chad J. Swanson more than expected).
Fields of papers citing papers by Chad J. Swanson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chad J. Swanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chad J. Swanson. The network helps show where Chad J. Swanson may publish in the future.
Co-authorship network of co-authors of Chad J. Swanson
This figure shows the co-authorship network connecting the top 25 collaborators of Chad J. Swanson. A scholar is included among the top collaborators of Chad J. Swanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chad J. Swanson. Chad J. Swanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Geerts, Hugo, Piet H. van der Graaf, Edgar Schuck, et al.. (2023). A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 12(4). 444–461.
2.
Berry, Donald A., Shobha Dhadda, Michio Kanekiyo, et al.. (2023). Lecanemab for Patients With Early Alzheimer Disease. JAMA Network Open. 6(4). e237230–e237230.
3.
Dyck, Christopher H. van, Chad J. Swanson, Paul Aisen, et al.. (2022). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 388(1). 9–21.
4.
McDade, Eric, Jeffrey L. Cummings, Shobha Dhadda, et al.. (2022). Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer s Research & Therapy. 14(1). 191–191.
5.
Irizarry, Michael C., Shobha Dhadda, Tanya Bogoslovsky, et al.. (2021). BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021). Neurology. 96(15_supplement).
6.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2020). A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease. Alzheimer s & Dementia. 16(S9).
7.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2020). Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330). Neurology. 94(15_supplement).
8.
Logovinsky, Veronika, Andrew Satlin, Robert Lai, et al.. (2016). Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimer s Research & Therapy. 8(1). 14–14.
9.
Swanson, Chad J., June Kaplow, Diego Mastroeni, et al.. (2013). P4–286: Pharmacology of BAN2401: A monoclonal antibody selective for beta‐amyloid protofibrils. Alzheimer s & Dementia. 9(4S_Part_20).
10.
Marsteller, Douglas, Christophe Gerald, Ronald Kong, et al.. (2008). The MCH1 receptor antagonist SNAP 94847 induces sensitivity to dopamine D2/D3 receptor agonists in rats and mice. European Journal of Pharmacology. 602(1). 66–72.
11.
David, Denis J., Kristen C. Klemenhagen, Michael Saxe, et al.. (2007). Efficacy of the MCHR1 Antagonist N-[3-(1-{[4-(3,4-Difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in Mouse Models of Anxiety and Depression following Acute and Chronic Administration Is Independent of Hippocampal Neurogenesis. Journal of Pharmacology and Experimental Therapeutics. 321(1). 237–248.
12.
Wolinsky, Toni D., Chad J. Swanson, Hai Zhong, et al.. (2006). The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain & Behavior. 6(7). 628–639.
13.
Swanson, Chad J., Mark G. Bures, Michael P. Johnson, et al.. (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Reviews Drug Discovery. 4(2). 131–144.
14.
Swanson, Chad J. & Darryle D. Schoepp. (2003). A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists. Annals of the New York Academy of Sciences. 1003(1). 309–317.
15.
Swanson, Chad J., Kenneth W. Perry, & Darryle D. Schoepp. (2003). The mGlu2/3 receptor agonist, LY354740, blocks immobilization‐induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. Journal of Neurochemistry. 88(1). 194–202.
16.
Swanson, Chad J. & Peter W. Kalivas. (2000). Regulation of Locomotor Activity by Metabotropic Glutamate Receptors in the Nucleus Accumbens and Ventral Tegmental Area. Journal of Pharmacology and Experimental Therapeutics. 292(1). 406–414.
17.
Stratford, Thomas R., Chad J. Swanson, & Ann E. Kelley. (1998). Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell. Behavioural Brain Research. 93(1-2). 43–50.
18.
Swanson, Chad J., Susan Heath, Thomas R. Stratford, & Ann E. Kelley. (1997). Differential Behavioral Responses to Dopaminergic Stimulation of Nucleus Accumbens Subregions in the Rat. Pharmacology Biochemistry and Behavior. 58(4). 933–945.
19.
Kelley, Ann E. & Chad J. Swanson. (1997). Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study. Behavioural Brain Research. 89(1-2). 107–113.
20.
Kelley, Ann E., Elizabeth P. Bless, & Chad J. Swanson. (1996). Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats.. Journal of Pharmacology and Experimental Therapeutics. 278(3). 1499–1507.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christoph Höck Breakdown of academic impact, for papers by Nenad Bogdanović Breakdown of academic impact, for papers by Judes Poirier Breakdown of academic impact, for papers by Zaven S. Khachaturian Breakdown of academic impact, for papers by Miloš D. Ikonomović Breakdown of academic impact, for papers by Chris G. Parsons Breakdown of academic impact, for papers by Jeffy P. Jimenez Breakdown of academic impact, for papers by Erik D. Roberson Breakdown of academic impact, for papers by Milene L. Brownlow Breakdown of academic impact, for papers by James J. Lah